Takeda snags EU backing for Crohn's drug; Biogen picks up Canadian nod for hemophilia hopeful;

@FierceBiotech: Versartis grabs $126M in an upsized IPO to fund its orphan drug. News | Follow @FierceBiotech

@JohnCFierce: Merck, Endocyte score crucial EMA OK for conditional approval of vintafolide. More | Follow @JohnCFierce

@DamianFierce: EU smiles on Lilly and Boehringer's FDA-rejected diabetes drug. Article | Follow @DamianFierce

@EmilyMFierce: Public-private Japanese partnership invests $15M in neglected diseases. Story | Follow @EmilyMFierce

> The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval for Takeda's ulcerative colitis and Crohn's disease drug vedolizumab, which the company plans to market as Entyvio. News

> Biogen Idec ($BIIB) won Canadian approval for Alprolix, its long-acting hemophilia B treatment. Article

> Forest Laboratories ($FRX) and partner Richter are touting positive Phase IIb results for cariprazine in major depressive disorder. The drug previously endured an FDA rejection in schizophrenia. Release

Medical Device News

@FierceMedDev: Is there such a thing as a 'gentle' colonoscopy device? Invendo thinks so--and brought in $28M for its new tool. Item | Follow @FierceMedDev

@MarkHFierce: Qiagen hit the Chinese market with its next-gen TB test. Competition looms. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: MedImmune inks licensing deal with Bioasis for brain delivery platform. Story via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Cochlear scored FDA approval for its innovative hearing aid system. Story | Follow @EmilyWFierce

> Beleaguered Orthofix brings in a new chairman. More

> Yes, U.S. med tech recalls have doubled since 2003--but so has the market. Story

Pharma News

@FiercePharma: Yesterday's top-read FiercePharmaManufacturing story: NVS CEO predicts generic industry fallout as quality takes center stage. More | Follow @FiercePharma

@TracyStaton: Contrary to popular belief, side-effect reports on new meds hit a steady pace, study finds. Story | Follow @TracyStaton

@EricPFierce: The FDA says it will boost foreign plant inspections 40%, and cut them by same amount in US. News | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Arkansas court boots $1.2B J&J verdict on technical grounds. Article | Follow @CarlyHFierce

> J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face. Story

> Wockhardt plants cited by Indian regulators. More

> Novo CEO sees improved picture for Tresiba in U.S. market. Piece

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.